The efficacy of different warfarin initiating dose in patients diagnosed with venous thromboembolism warfarin,
Conditions
Interventions
The eligible patients were randomized by blocked randomization to receive a warfarin initiating dose of 3 mg or 5 mg per day for the first 2 consecutive days (day 1 and day 2). The first day of warfar
and then heparin therapy was discontinued. The choice of heparin treatment was made according to the attending physician’s discretion. Blood samples were collected from venipuncture and were sent fo
INR,
aPTT,
complete blood count and a liver function test prior to the initiation of warfarin anticoagulant therapy. In addition,
blood for INR testing was collected on days 3,
5 and 8 of warfarin treatment. Furthermore,
blood samples were drawn and sent for evaluation of single nucleotide polymorphisms (SNPs) of the CYP2C9 and VKORC1 genes.
The enrolled inpatients or outpatients were followed on days 3,
and 8 of warfarin treatment.
,The eligible patients were randomized by blocked randomization to receive a warfarin initiating dose of 3 mg or 5 mg per day for the first 2 consecutive days (day 1 and d
and then heparin therapy was discontinued. The choice of heparin treatment was made according to the attending physician’
Active Comparator Drug,Active Comparator Drug
Warfarin 3-
mg initiating dose and corresponding dosing schedule,Warfarin 5-
mg initiating dose and corresponding dosing schedule
Sponsors
Faculty of Medicine Siriraj Hospital, Mahidol University
Thai Society of Hematology
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Adult patients aged 18 years or older who were diagnosed with symptomatic proximal deep vein thrombosis (DVT) of the extremity or DVT at other unusual sites (for example, cerebral venous sinus thrombosis, and/or pulmonary embolism (PE)) and planned to receive warfarin with a target INR of 2.0–3.0.
Exclusion criteria
Exclusion criteria: An absolute contraindication to anticoagulant therapy (e.g., active bleeding), high risk of bleeding (e.g., recent eye, brain or spinal cord surgery within 3 months), history of concurrent congestive heart failure, history of liver cirrhosis (Child Pugh class B or C), concomitant use of aspirin, prolonged baseline PT and/or activated partial thromboplastin time (aPTT) above the upper normal limits, platelet counts of less than 50×109/L, serum albumin less than 2.0 g/dL, pregnancy, and patients who were unable to perform oral feeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy of warfarin initiating dose and the corresponding dosing schedule 8 days The number of patients who achieved the INR of 2.0–3.0 within 8 days after treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Bleeding complication 8 days The incidence of bleeding complications within 8 days or INR > 5.0 ,Characteristics of CYP2C9 and VKORC1 single nucleotide polymorphisms 8 days Genotyping of CYP2C9 and VKORC1 | — |
Countries
Thailand
Contacts
Public ContactBundarika Suwanawiboon
Faculty of Medicine Siriraj Hospital
Outcome results
None listed